<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HA0C4B4442A1046858C7E3403EE87D5A4" public-private="public" bill-type="olc"> 
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 1455 IH: Speeding Access to Already Approved Pharmaceuticals Act of 2015</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-03-18</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code> 
<congress>114th CONGRESS</congress> <session>1st Session</session> 
<legis-num>H. R. 1455</legis-num> 
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber> 
<action> 
<action-date date="20150318">March 18, 2015</action-date> 
<action-desc><sponsor name-id="S001187">Mr. Stivers</sponsor> (for himself and <cosponsor name-id="R000577">Mr. Ryan of Ohio</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc> 
</action> 
<legis-type>A BILL</legis-type> 
<official-title>To require the Food and Drug Administration to expedite review of pharmaceuticals that are approved for marketing in the European Union.</official-title> 
</form> 
<legis-body id="H1CF39A96224E4BC281542C2CF0F9B735" style="OLC"> 
<section id="HA6BCFC30EAA346FDBF9EB9A7664B42F3" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Speeding Access to Already Approved Pharmaceuticals Act of 2015</short-title></quote>.</text></section> <section id="H4919BA2F3C174326999CBD202A125877"><enum>2.</enum><header>Expedited review of EU-approved pharmaceuticals</header> <subsection id="HBEFAD33B4F544DA5B6CB7305EEA8075A"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 506 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356">21 U.S.C. 356</external-xref>) is amended by adding at the end the following:</text> 
<quoted-block style="OLC" id="HD4626756D91842BA81391BC5C907765C" display-inline="no-display-inline"> 
<subsection id="H7F576CE569C14D15A9978019AD61CBEE"><enum>(g)</enum><header>EU-Approved pharmaceuticals</header> 
<paragraph id="H8E334C3804F64593A00025419E8F1AD8"><enum>(1)</enum><header>Expedited review</header><text>Beginning not later than 90 days after a new pharmaceutical is approved for marketing in the European Union, the Secretary shall, at the request of the sponsor of the pharmaceutical, facilitate the development and expedite the review of such new pharmaceutical under section 505 or 515 of this Act or section 351 of the Public Health Service Act, as appropriate.</text></paragraph> <paragraph id="H94E43F70DB4349F691D6D6A324C29DE1"><enum>(2)</enum><header>Definition</header><text>In this subsection, the term <term>pharmaceutical</term> means a drug (including a biological product) or a device. </text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection> 
<subsection id="H0E578FCDC444463EA4C442632A7AF0A2"><enum>(b)</enum><header>Technical correction</header><text display-inline="yes-display-inline">Subsection (f) (relating to awareness efforts) of section 506 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356">21 U.S.C. 356</external-xref>) is hereby moved so as to follow subsection (e) (relating to construction) of such section 506.</text></subsection></section> </legis-body> </bill> 

